Patheon enlarges dollar loan and cuts margins sharply
Toronto-listed pharmaceuticals firm Patheon has signed a new seven year covenant-lite loan package. A healthy oversubscription allowed it to increase the dollar tranche and substantially tighten price margins.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
